Zenas BioPharma, Inc. (ZBIO) Market Cap & Valuation Ratios
Zenas BioPharma, Inc. (ZBIO) has a market cap of $1.8B and a price-to-sales ratio of 1751.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ZBIOZenas BioPharma, Inc.Follow ZBIO — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ZBIO | 1.8 | — | — | — | -12.9% | -93% | — | -137% |
| SEPN | 1.9 | — | 15.3 | — | 5.6% | — | -44% | -18% |
| SRPT | 1.9 | — | 1.0 | — | 4.4% | -20% | -7% | -8% |
| XNCR | 1.9 | — | 15.2 | — | -11.1% | -29% | -206% | -34% |
| MLYS | 1.8 | — | — | — | -7.6% | — | — | -73% |
| PVLA | 1.8 | — | — | — | — | — | — | -199% |
| TRVI | 1.8 | — | — | — | -2.9% | — | — | -34% |
| VIR | 1.8 | — | 4.2 | — | -11.4% | +1496% | -92% | -39% |
| MAZE | 1.7 | — | — | — | -6.2% | — | — | -50% |
| URGN | 1.7 | — | 9.4 | — | -9.4% | +100% | -35% | — |
| KLRA | 1.7 | — | — | — | — | — | — | — |
| Median of these 10 | — | 9.4 | — | -6.9% | +40% | -44% | -37% |
.
Growth vs. price
each dot a company · hover or tap for valuesZenas BioPharma, Inc. — questions
- What is Zenas BioPharma, Inc.'s market cap?
- $1.8B.
- What is Zenas BioPharma, Inc.'s price-to-sales ratio?
- 1751.3.
Every figure on this page comes from Zenas BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.